Patent Expiry

Patent/Exclusivity Expiry: IMKELDI

Other upcoming events for TENX

Phase 3 ReadoutPhase 3 Topline: A Phase 3, Double-Blind, Randomized, Placebo-Controlled Study of Levosimendan in Pulmonary Hypertens
Phase 3 ReadoutPhase 3 Topline: A Multicenter, Open-Label, Long-Term Extension Study for Oral Levosimendan (TNX-103)
Phase 3 ReadoutPhase 3 Topline: A Phase 3, Double-Blind, Randomized, Placebo-Controlled Study of Levosimendan in Pulmonary Hypertens

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start FreeFull Calendar
    Patent/Exclusivity Expiry: IMKELDI — TENX Patent Expiry | BioSniper